These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

986 related articles for article (PubMed ID: 31407311)

  • 1. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
    Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
    J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.
    Katoh N; Kataoka Y; Saeki H; Hide M; Kabashima K; Etoh T; Igarashi A; Imafuku S; Kawashima M; Ohtsuki M; Fujita H; Arima K; Takagi H; Chen Z; Shumel B; Ardeleanu M
    Br J Dermatol; 2020 Jul; 183(1):39-51. PubMed ID: 31564057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
    Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
    J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
    Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
    JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials.
    Alexis AF; Rendon M; Silverberg JI; Pariser DM; Lockshin B; Griffiths CE; Weisman J; Wollenberg A; Chen Z; Davis JD; Li M; Eckert L; Gadkari A; Shumel B; Rossi AB; Graham NM; Ardeleanu M
    J Drugs Dermatol; 2019 Aug; 18(8):804-813. PubMed ID: 31424712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
    Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
    Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
    Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
    Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 Jun; 182(6):e186-e209. PubMed ID: 32476149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
    Silverberg JI; Lynde CW; Abuabara K; Patruno C; de Benedetto A; Zhang H; Thomas RB; Bégo-Le-Bagousse G; Khokhar FA; Vakil J; Marco AR; Levit NA
    Am J Clin Dermatol; 2023 May; 24(3):469-483. PubMed ID: 36808602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
    Siegfried EC; Bieber T; Simpson EL; Paller AS; Beck LA; Boguniewicz M; Schneider LC; Khokhar FA; Chen Z; Prescilla R; Mina-Osorio P; Bansal A
    Am J Clin Dermatol; 2021 Mar; 22(2):243-255. PubMed ID: 33655423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
    Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
    Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis.
    Boguniewicz M; Beck LA; Sher L; Guttman-Yassky E; Thaçi D; Blauvelt A; Worm M; Corren J; Soong W; Lio P; Rossi AB; Lu Y; Chao J; Eckert L; Gadkari A; Hultsch T; Ruddy M; Mannent LP; Graham NMH; Pirozzi G; Chen Z; Ardeleanu M
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1212-1223.e6. PubMed ID: 33453450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
    Griffiths C; de Bruin-Weller M; Deleuran M; Fargnoli MC; Staumont-Sallé D; Hong CH; Sánchez-Carazo J; Foley P; Seo SJ; Msihid J; Chen Z; Cyr SL; Rossi AB
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1357-1372. PubMed ID: 34142350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
    Paller AS; Wollenberg A; Siegfried E; Thaçi D; Cork MJ; Arkwright PD; Gooderham M; Sun X; O'Malley JT; Khokhar FA; Vakil J; Bansal A; Rosner K; Shumel B; Levit NA
    Paediatr Drugs; 2021 Sep; 23(5):515-527. PubMed ID: 34462864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
    Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
    J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 50.